Repligen Corporation's stock fell 28% in the first quarter after its forward guidance factored in uncertainty regarding biopharmaceutical industry capital expenditures and the pace of FDA approvals. The company reported fourth quarter revenues and earnings that were ahead of consensus, but the cautious outlook caused the sell-off. Repligen is a global life sciences company offering bioprocessing technologies and solutions used in manufacturing biological drugs. The stock closed at $137.00 per share on June 29, 2026, with a market capitalization of $7.73 billion.
Repligen CorporationForward guidance uncertainty due to biopharma capex and FDA approval pace caused stock to fall 28%
MicroStrategy Incorporated